In this article:
Blurbs

ProQR (PRQR) Gets a Buy Rating from JMP Securities

In this article:
In this article:

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on ProQR (PRQRResearch Report), with a price target of $31.00. The company’s shares closed last Wednesday at $6.81.

According to TipRanks.com, Wolleben is a 4-star analyst with an average return of 23.2% and a 50.0% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Clearside Biomedical, and Ocular Therapeutix.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $23.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.46 and a one-year low of $3.40. Currently, ProQR has an average volume of 447.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Read More on PRQR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More